Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX - Free Report) in a research note published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $10.00 price target on the biopharmaceutical company's stock.

Several other equities research analysts also recently commented on LXRX. StockNews.com raised Lexicon Pharmaceuticals to a "sell" rating in a research report on Tuesday, July 9th. Leerink Partners set a $6.00 price objective on shares of Lexicon Pharmaceuticals and gave the company an "outperform" rating in a research note on Friday, October 18th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $8.00.

Lexicon Pharmaceuticals Stock Down 4.1 %

NASDAQ LXRX traded down $0.08 on Wednesday, hitting $1.86. 3,208,574 shares of the company were exchanged, compared to its average volume of 3,379,091. The company has a current ratio of 11.51, a quick ratio of 11.49 and a debt-to-equity ratio of 0.41. The company has a market cap of $458.00 million, a PE ratio of -2.24 and a beta of 1.28. The stock has a fifty day moving average of $1.71 and a 200-day moving average of $1.77. Lexicon Pharmaceuticals has a 12 month low of $0.92 and a 12 month high of $3.73.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.01. Lexicon Pharmaceuticals had a negative net margin of 5,509.34% and a negative return on equity of 105.38%. The company had revenue of $1.65 million for the quarter, compared to analysts' expectations of $2.74 million. During the same quarter in the prior year, the firm earned ($0.22) EPS. As a group, analysts forecast that Lexicon Pharmaceuticals will post -0.69 earnings per share for the current year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of LXRX. BNP Paribas Financial Markets grew its stake in shares of Lexicon Pharmaceuticals by 82.6% in the 1st quarter. BNP Paribas Financial Markets now owns 59,378 shares of the biopharmaceutical company's stock worth $143,000 after acquiring an additional 26,859 shares in the last quarter. Vanguard Group Inc. boosted its position in Lexicon Pharmaceuticals by 7.0% in the first quarter. Vanguard Group Inc. now owns 6,401,225 shares of the biopharmaceutical company's stock worth $15,363,000 after purchasing an additional 420,854 shares during the last quarter. Boulder Hill Capital Management LP bought a new position in Lexicon Pharmaceuticals in the 1st quarter valued at $615,000. Virtu Financial LLC purchased a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter valued at $105,000. Finally, Hennion & Walsh Asset Management Inc. bought a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter worth $912,000. 74.70% of the stock is owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.